| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
14C-Cyproconazole (>98% radiochemical purity) was mixed with SAN 1414 F 360 SL 001 BS (6.41% w/w cyproconazole, 300 g/L didecyldimethylammonium chloride) to a final nominal radioactive concentration of 1 uCi/18 mg, at nominal doses of 0.641, 0.01, or 0.0012 mg ai/sq cm. ... The formulated test substance was applied to excised rat skin or human skin (1.77 sq cm/sample) mounted in an in vitro dermal penetration cell. Ten samples of each type of tissue were treated and results from the first five were reported. ... The rate of penetration of 14-C-cyproconazole following dermal application was greater through rat skin than through human skin. The rate of penetration of the undiluted formulation through rat skin was 12.30 ug/sq cm/hr compared to 0.501 ug/sq cm/hr for human skin. As the dilution factor increased, the rate of penetration decreased, and the permeability coefficients increased. Metabolism / Metabolites ... The metabolism of cyproconazole is similar in ruminants and poultry. The major routes of metabolism involved either hydroxylation of the carbon bearing the cyclopropyl group or elimination of the methyl-cyclopropyl chain followed by reduction. Hydroxylation of the methyl group was also a major route of metabolism, as was opening and modification of the cyclopropyl ring. The data indicate that there is only limited cleavage of the triazole ring and that the majority of residues retain the intact phenyl and triazole rings. Cyproconazole (free and conjugated) was the only significant (>10%) residue identified in plant metabolism studies (other than the triazole related metabolites). |
|---|---|
| Toxicity/Toxicokinetics |
Non-Human Toxicity Values
LD50 Mouse oral 352 mg/kg /from table/ LD50 Rat oral 1020 mg/kg (male) and 1330 mg/kg (female) LD50 Rat oral 1020 mg/kg /from table/ LD50 Rat oral 2054 mg/kg in males and females For more Non-Human Toxicity Values (Complete) data for CYPROCONAZOLE (8 total), please visit the HSDB record page. |
| Additional Infomation |
2-(4-chlorophenyl)-3-cyclopropyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol is a tertiary alcohol that is butan-2-ol substituted by a 4-chlorophenyl group at position 2, a cyclopropyl group at position 3 and a 1H-1,2,4-triazol-1-yl group at position 1. It is a member of monochlorobenzenes, a tertiary alcohol, a member of triazoles and a member of cyclopropanes.
Cyproconazole formula 360 SL is a water-based wood preservative that prevents decay from fungi in above-ground applications. It is not intended to protect wood that is in contact with the ground. Where there is the potential for insect attack, a registered insecticide should also be used. |
| Molecular Formula |
C15H18CLN3O2S
|
|---|---|
| Molecular Weight |
291.77
|
| Exact Mass |
291.114
|
| CAS # |
94361-06-5
|
| PubChem CID |
86132
|
| Appearance |
Colorless crystals from hexane/CH2Cl2
Colorless solid |
| Density |
1.32
|
| Boiling Point |
>250ºC
|
| Melting Point |
106.2-106.9ºC
|
| Flash Point |
>100 °C
|
| LogP |
2.865
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
20
|
| Complexity |
331
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C=CC(C(C(C2CC2)C)(CN2C=NC=N2)O)=CC=1
|
| InChi Key |
UFNOUKDBUJZYDE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H18ClN3O/c1-11(12-2-3-12)15(20,8-19-10-17-9-18-19)13-4-6-14(16)7-5-13/h4-7,9-12,20H,2-3,8H2,1H3
|
| Chemical Name |
2-(4-chlorophenyl)-3-cyclopropyl-1-(1,2,4-triazol-1-yl)butan-2-ol
|
| Synonyms |
HSDB 7706; Atemi; Alto 100SL
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~342.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (8.57 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.57 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4274 mL | 17.1368 mL | 34.2736 mL | |
| 5 mM | 0.6855 mL | 3.4274 mL | 6.8547 mL | |
| 10 mM | 0.3427 mL | 1.7137 mL | 3.4274 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
